Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction
Clinical Evaluation of Hyper-Diluted Calcium Hydroxylapatite Versus Hyaluronic Acid in the Reconstruction of Interdental Papilla Deficiencies: A Split-Mouth Study
This study aims to compare two injectable materials, calcium hydroxylapatite (Radiesse®) and hyaluronic acid, for treating gaps between the teeth caused by loss of gum tissue. These gaps, commonly known as "black triangles," can affect the appearance of a person's smile and may cause food to become trapped between the teeth.
Hyaluronic acid has been used to improve the appearance of these gaps, but its effects may not last for a long time. Calcium hydroxylapatite is another injectable material that may help the body produce collagen, a natural protein that supports gum tissue. This study will investigate whether calcium hydroxylapatite can provide better or longer-lasting results compared with hyaluronic acid.
The study will take place at the Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia. Approximately 20 healthy adults who have two similar gaps between their front teeth will be invited to participate.
Each participant will receive both treatments. One gap will be treated with diluted calcium hydroxylapatite, while the other will be treated with hyaluronic acid. The treatment for each site will be selected randomly to ensure a fair comparison. Each site will receive one injection.
Participants will be examined before treatment and again after 3 weeks, 3 months, and 6 months to assess the results.
During these visits, photographs and clinical measurements will be taken to evaluate changes in the size of the gaps and the amount of gum tissue between the teeth. Participants will also be asked about their satisfaction with the appearance of their gums, any discomfort experienced during treatment, and whether they have noticed an improvement in their smile. Any side effects or complications will also be recorded.
The researchers will compare how well the two materials improve the appearance of the gaps and how long the improvements last.
Participation will be voluntary, and all participants will receive information about the study before signing a consent form. Their personal information will be kept confidential, and they may withdraw from the study at any time without affecting their dental care.
The main goal of this study is to identify whether diluted calcium hydroxylapatite or hyaluronic acid provides better and longer-lasting improvement in the appearance of gaps between the teeth. The findings may help dentists choose more effective, minimally invasive treatments for patients with missing gum tissue between their teeth.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults aged 18 years or older.
- Systemically healthy individuals with no history of chronic systemic diseases.
- Patients with a healthy periodontium.
- Patients presenting with two comparable interdental papilla deficiencies in the esthetic zone.
- Patients with Class I interdental papilla loss according to the Nordland and Tarnow classification.
Exclusion Criteria:
- Patients with chronic systemic diseases.
- Pregnant or lactating women.
- Current smokers.
- Children and adolescents under 18 years of age.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Hyper-Diluted Calcium Hydroxylapatite (Radiesse®)
Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyper-diluted calcium hydroxylapatite (Radiesse®), prepared at a 1:2 dilution ratio using saline and lidocaine. The intervention aims to improve interdental papillary fill and stimulate collagen production, potentially providing longer-lasting tissue improvement. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment. |
Hyper-diluted calcium hydroxylapatite (Radiesse®) will be used for the treatment of Class I interdental papilla deficiencies. The material will be prepared at a 1:2 dilution ratio using saline and lidocaine, mixed through a Luer-lock syringe connection. Each randomly assigned interdental site will receive a single injection. The treatment aims to stimulate collagen production, improve interdental papillary fill, and enhance soft tissue volume and stability. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. |
|
Comparador activo: Hyaluronic Acid (HA)
Interdental papilla deficiencies assigned to this treatment will receive a single injection of hyaluronic acid (HA). The intervention aims to improve interdental papillary fill by increasing soft tissue volume and reducing the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months following treatment. |
Hyaluronic acid (HA) injectable filler will be used for the treatment of Class I interdental papilla deficiencies. Each randomly assigned interdental site will receive a single injection of HA to increase soft tissue volume, improve interdental papillary fill, and reduce the appearance of black triangles. Clinical outcomes will be evaluated at baseline, 3 weeks, 3 months, and 6 months after treatment. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Reduction in Black Triangle Area
Periodo de tiempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in the area of the open gingival embrasure (black triangle) following treatment, measured in square millimeters (mm²) using standardized calibrated digital clinical photographs. The reduction in black triangle area will be compared between the calcium hydroxylapatite and hyaluronic acid treatment sites to evaluate the effectiveness of papillary reconstruction. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
|
Change in Interdental Papilla Height
Periodo de tiempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in interdental papilla height (mm) from baseline following treatment with hyper-diluted calcium hydroxylapatite or hyaluronic acid. Papillary height will be measured using standardized digital clinical photographs calibrated with a UNC-15 periodontal probe and analyzed using image-analysis software (ImageJ). The distance from the papilla tip to a reference line connecting the adjacent gingival margins will be measured. Changes in papillary height will be compared between the two treatment sites. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Interdental Papilla Thickness
Periodo de tiempo: Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
Change in interdental papilla thickness (mm) following treatment with calcium hydroxylapatite or hyaluronic acid. Tissue thickness will be assessed using a calibrated endodontic file fitted with a silicone stopper at a standardized reference point. Changes in tissue thickness will be compared between treatment sites to estimate improvements in papillary tissue bulk. |
Baseline, 3 weeks, 3 months, and 6 months after treatment.
|
|
Patient Satisfaction With Esthetic Outcomes
Periodo de tiempo: 3 weeks, 3 months, and 6 months after treatment.
|
Patient satisfaction with the appearance of the treated interdental papilla will be assessed using a Visual Analog Scale (VAS). Participants will evaluate their satisfaction with the esthetic improvement achieved following each treatment. Satisfaction scores will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Global Aesthetic Improvement Scale (GAIS)
Periodo de tiempo: 3 weeks, 3 months, and 6 months after treatment.
|
Esthetic improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS), a five-point scale ranging from "worse" to "very much improved." Both participants and investigators will evaluate the improvement in interdental papilla appearance compared with baseline. Scores will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Stability of Interdental Papillary Fill
Periodo de tiempo: 3 weeks, 3 months, and 6 months after treatment.
|
The stability of interdental papillary reconstruction will be evaluated by comparing changes in papilla height and black triangle dimensions across follow-up visits. The maintenance of treatment-related improvements at 6 months will be assessed to compare the durability of calcium hydroxylapatite and hyaluronic acid injections. |
3 weeks, 3 months, and 6 months after treatment.
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient Satisfaction Questionnaire (PSQ-18)
Periodo de tiempo: 3 weeks, 3 months, and 6 months after treatment.
|
Patient-reported satisfaction will be evaluated using the Patient Satisfaction Questionnaire Short Form (PSQ-18), consisting of 18 items. The questionnaire will assess satisfaction with treatment, comfort, perceived improvement, and overall treatment experience. Responses will be compared between the two treatment sites. |
3 weeks, 3 months, and 6 months after treatment.
|
|
Adverse Events and Complications
Periodo de tiempo: From the injection procedure through the 6-month follow-up period.
|
Any adverse effects or complications associated with calcium hydroxylapatite or hyaluronic acid injections will be recorded and compared between the treatment sites. The number and nature of reported complications will be documented to evaluate the safety of both interventions. |
From the injection procedure through the 6-month follow-up period.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- 132-09-26
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .